Specify a stock or a cryptocurrency in the search bar to get a summary
Cipla Limited
CIPLACipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Address: Cipla House, Mumbai, India, 400013
Analytics
WallStreet Target Price
123 445.22 INRP/E ratio
28.3376Dividend Yield
0.83 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CIPLA
Dividend Analytics CIPLA
Dividend growth over 5 years
183 %Continuous growth
1 yearPayout Ratio 5 years average
16 %Dividend History CIPLA
Stock Valuation CIPLA
Financials CIPLA
Results | 2019 | Dynamics |